Coronavirus disease (COVID-19), HIV & hepatitis C: What you need to know

CATIE (Canada), 17 March 2020

  • An HIV-positive person on effective treatment is not expected to be at higher risk of becoming seriously ill with COVID-19
  • A person with untreated HIV or a low CD4+ cell count may be at higher risk of becoming seriously ill with COVID-19
  • People with HIV or hepatitis C are more likely to have other conditions that carry a greater risk of becoming seriously ill with COVID-19

 

 

Update on COVID-19 for PLHIV

SAMESH, March 19, 2020

SAMESH, SHINE SA, and Thorne Harbour Health are encouraging people living with HIV (PLHIV) to take additional precautions in the face of the changing landscape around 2019 novel coronavirus (COVID-19).

We want to ensure the ongoing health and wellbeing of all PLHIV who are more vulnerable to COVID-19. This means minimising the risk of exposure to the virus.

While everyone is at risk of contracting COVID-19, the consequences of infection are more severe for some vulnerable groups. This includes PLHIV who are:

  • Aged over 60 years old
  • Living with a detectable viral load or a CD4 count below 500
  • Diabetic
  • Smokers
  • Living with hepatitis B or C
  • Living with a comorbidity such as heart or lung issues

Those PLHIV on treatment with an undetectable viral load (and no other significant health condition) are at no greater risk of serious health consequences due to COVID-19 than the general population. That being said, they should still take the advice of the health department in exercising precautions such as handwashing, working from home where possible, limiting time on public transport, and avoiding large groups or crowded areas.

Those PLHIV who fall into one of the vulnerable groups listed above should limit contact with others to avoid potential exposure to COVID-19.

If you are living with HIV and are concerned you might be at risk, you should:

  • Maintain regularly scheduled medical appointments, but consider asking your doctor about telehealth consultations
  • Ensure you have between 1-3 month supply of any medications you currently take
  • Avoid stockpiling medications beyond a 1-3 month supply as this could cause unnecessary shortages
  • Be wary of advice or articles in social media — do not modify the medications you currently take without first consulting your doctor
  • Contact your doctor about getting vaccinations for influenza and pneumococcal when available
  • Keep in touch with friends, colleagues, and family via phone calls and video chat — consider scheduling regular catch ups
  • Stay in touch – our organisations will continue to release more information and resources as the situation continues to evolve

This public health issue can be stressful, but our communities have a long history of staying informed and collective action to ensure we look after our health as well as the wellbeing of those around us. Let’s keep this legacy going as we look after ourselves and those around us

What’s new in HIV and hep C? An update for Aboriginal and Torres Strait Islander health workers

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), June 2019

This Deadly Sex Update webinar provides Aboriginal and Torres Strait Islander health and community workers with an introduction and the latest news in hepatitis C and HIV.

The information presented supports health workers to discuss key messages with clients and the community around hep C and HIV, including testing, prevention, current treatments and management.

Presenter: Dr Darren Russell, Director of Cairns Sexual Health.
Presented on: Monday 10 June 2019

What’s new in HIV and hep C? An update for Aboriginal and Torres Strait Islander health workers. Dr Darren Russell, June 2019 from ASHM on Vimeo.

HIV and viral hepatitis disclosure [in South Australia] – factsheet

SA Health, updated 2019

Deciding to disclose your HIV or viral hepatitis (hepatitis B or hepatitis C) status is a personal choice. There are few situations where you are legally required to disclose your HIV or viral hepatitis status, however, there may be times when it’s in your best interests to disclose your status even if you are not legally required to do so.

 

Striving towards the elimination of HCV infection among PWID

International Journal of Drug Policy, Volume 72,Pages 1-198 (October 2019)

Nearly 200 pages of open access articles from projects and research around the world.

While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.

  • Browse articles here
  • You can also download the full issue as PDF by creating an account and signing in at the above link

In contrast to Australia’s success with hepatitis C, our response to hepatitis B is lagging

The Conversation, October 15th, 2019

Around one-third of Australians living with hepatitis C have been cured in the last four years. Australia’s response to hepatitis C is seen as a leading example around the world, and the elimination of the disease as a major public health threat is looking like an increasingly achievable goal.

But the situation is much less promising for Australians living with hepatitis B, which is now the most common blood-borne viral infection in Australia. It affects more people than hepatitis C and HIV combined.